Ondansetron Tablet, Film Coated
Product Images NDC 16714-159

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Ondansetron (NDC 16714-159). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Package Label-principal Display Panel (4 mg Blister Carton (10 x 10 Unit-dose))

Each tablet of this medicine contains Ondansetron hydrochloride USP as its active ingredient. It is manufactured by Aurobindo Pharma Limited in Hyderabad, India, for Northstar Rx LLC, a subsidiary of Nortstar Healthcare Holdings. The medicine is used for the prevention of nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. The recommended dosage is mentioned in the package insert. The tablets should be stored in a tightly closed container at a temperature between 20°C and 25°C, protected from light. This information was last updated in March 2021.*

FDA Label Image

Package Label-principal Display Panel (8 mg (500 Tablet Bottle))

Each tablet of this medication contains ondansetron hydrochloride and is manufactured by Aurobindo Pharma Limited. The usual dosage should be followed as per the instructions provided in the package insert. The tablets should be stored in a light-resistant container and protected from light. The medication is distributed by Northstar Rx LLC and dispensed in an 8 mg container. The NDC for this medication is 16714-160-01. This information is valid as of March 2021.*

FDA Label Image

Chemical Structure (Ondansetron Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.